uuid:
  -
    value: 3fa57777-77a7-4f2b-9b53-95b1dcc62cbd
langcode:
  -
    value: und
type:
  -
    target_id: case_series
    target_type: node_type
    target_uuid: 0ea0fe3a-e616-4d45-88b7-f6bb126fd852
revision_timestamp:
  -
    value: '2018-08-15T17:55:39+00:00'
    format: 'Y-m-d\TH:i:sP'
revision_uid:
  -
    target_type: user
    target_uuid: 96ae2d29-6a92-4a0b-b9de-690de490c603
revision_log: {  }
status:
  -
    value: true
uid:
  -
    target_type: user
    target_uuid: 96ae2d29-6a92-4a0b-b9de-690de490c603
title:
  -
    value: 'Valeant''s Battle for Allergan'
created:
  -
    value: '2018-08-15T17:55:39+00:00'
    format: 'Y-m-d\TH:i:sP'
changed:
  -
    value: '2018-08-15T17:55:39+00:00'
    format: 'Y-m-d\TH:i:sP'
promote:
  -
    value: false
sticky:
  -
    value: false
default_langcode:
  -
    value: true
revision_translation_affected:
  -
    value: true
path:
  -
    alias: /faculty-and-research/case-series/id/a06-18-0005
body:
  -
    value: '<p>On April 21, 2014 two companies, Valeant Pharmaceuticals and Pershing Square,&nbsp;announced an unsolicited merger offer for Allergan Pharmaceuticals. The unsolicited offer&nbsp;quickly turned into a hostile acquisition. The following months saw a raging public debate&nbsp;over the future control of Allergan and its primary product, Botox, as well as the business&nbsp;strategies and philosophies of the two offering firms and their CEOs.</p>'
    format: basic_html
    processed: ''
    summary: ''
    summary_processed: ''
field_case_number:
  -
    value: A06-18-0005
field_case_page_length:
  -
    value: '18'
field_case_series_author:
  -
    target_type: taxonomy_term
    target_uuid: 9b4ad240-d748-42b9-ae24-15871020bcfa
field_case_series_date: {  }
field_case_series_image: {  }
field_case_series_industry:
  - {  }
field_case_series_year:
  -
    value: '2018-01-01'
field_case_setting:
  -
    value: USA
field_case_source:
  -
    value: Library
field_case_subject:
  -
    target_type: taxonomy_term
    target_uuid: 5d6eba99-f8ab-4ad8-88bc-9d20e713d129
field_fields:
  -
    target_type: taxonomy_term
    target_uuid: 05f89050-5790-44f5-a957-f1ec4d2ecee4
  -
    target_type: taxonomy_term
    target_uuid: 507c0265-2c02-4a8a-a94e-ca9ce40c9b78
  -
    target_type: taxonomy_term
    target_uuid: bd8c2f59-a006-4b52-9ba5-aeb56c1427ac
field_teaching:
  -
    value: 'This case has been used in both graduate business and management degree and non-degree programs to provide a platform for discussions of a number of differing issues, including mergers and acquisitions, corporate governance and control, activist investing, organic versus acquisition-based growth, and the mechanics of friendly and hostile acquisitions.'
_content_sync:
  entity_type: node
  entity_dependencies:
    user:
      - user.user.96ae2d29-6a92-4a0b-b9de-690de490c603
    taxonomy_term:
      - taxonomy_term.case_series_authors.9b4ad240-d748-42b9-ae24-15871020bcfa
      - taxonomy_term.case_series_categories.5d6eba99-f8ab-4ad8-88bc-9d20e713d129
      - taxonomy_term.case_series_fields.05f89050-5790-44f5-a957-f1ec4d2ecee4
      - taxonomy_term.case_series_fields.507c0265-2c02-4a8a-a94e-ca9ce40c9b78
      - taxonomy_term.case_series_fields.bd8c2f59-a006-4b52-9ba5-aeb56c1427ac
